Skip to main content Accessibility help
×
Home

Olanzapine versus placebo for out-patients with anorexia nervosa

  • E. Attia (a1) (a2) (a3), A. S. Kaplan (a4), B. T. Walsh (a1) (a2), M. Gershkovich (a5), Z. Yilmaz (a4), D. Musante (a6) and Y. Wang (a7)...

Abstract

Background

Anorexia nervosa (AN) is a serious psychiatric illness associated with significant morbidity and mortality. There is little empirical support for specific treatments and new approaches are sorely needed. This two-site study aimed to determine whether olanzapine is superior to placebo in increasing body mass index (BMI) and improving psychological symptoms in out-patients with AN.

Method

A total of 23 individuals with AN were randomly assigned in double-blind fashion to receive olanzapine or placebo for 8 weeks together with medication management sessions that emphasized compliance. Weight, other physical assessments and measures of psychopathology were collected.

Results

End-of-treatment BMI, with initial BMI as a covariate, was significantly greater in the group receiving olanzapine [F(1, 20)=6.64, p=0.018]. Psychological symptoms improved in both groups, but there were no statistically significant group differences. Of the 23 participants, 17 (74%) completed the 8-week trial. Participants tolerated the medication well with sedation being the only frequent side effect and no adverse metabolic effects were noted.

Conclusions

This small study suggests that olanzapine is generally well tolerated by, and may provide more benefit than placebo for out-patients with AN. Further study is indicated to determine whether olanzapine may affect psychological symptoms in addition to BMI.

Copyright

Corresponding author

*Address for correspondence: E. Attia, M.D., NYS Psychiatric Institute, Room 2214/Unit 98, 1051 Riverside Drive, New York, NY 10032, USA. (Email: ea12@columbia.edu)

References

Hide All
Beck, AT, Epstein, N, Brown, G, Steer, RA (1988). An inventory for measuring clinical anxiety: psychometric properties. Journal of Consulting and Clinical Psychology 56, 893897.
Beck, AT, Ward, CH, Mendelson, M, Mock, J, Erbaugh, J (1961). An inventory for measuring depression. Archives of General Psychiatry 4, 561571.
Bissada, H, Tasca, GA, Barber, AM, Bradwejn, J (2008). A double blind randomized placebo-controlled trial of olanzapine in the treatment of low weight and obsessional thinking in women with anorexia. American Journal of Psychiatry 165, 12811288.
Brambilla, F, Garcia, CS, Fassino, S, Daga, GA, Favaro, A, Santonastaso, P, Ramaciotti, C, Bondi, E, Mellado, C, Borriello, R, Monteteone, P (2007). Olanzapine therapy in anorexia nervosa; psychological effects. International Clinical Psychopharmacology 22, 197204.
Cooper, PJ, Taylor, MJ, Cooper, Z, Fairburn, CG (1987). The development and validation of the Body Shape Questionnaire. International Journal of Eating Disorders 6, 485494.
Fairburn, CG, Cooper, Z (1993). The eating disorder examination (12th edn). In Binge Eating: Nature, Assessment and Treatment(ed. Fairburn, C. G. and Wilson, G. T.), pp. 317360. Guilford Press: New York.
First, MB, Spitzer, RL, Gibbon, M, Janet, BW (1996). Structured Clinical Interview for DSM-IV Disorders. American Psychiatric Press, Inc.: Washington, DC.
Garner, DM, Olmsted, MP (1984). The Eating Disorder Inventory Manual. Psychological Assessment Resources: Odessa.
Halmi, KA, Agras, WS, Crow, S, Mitchell, J, Wilson, GT, Bryson, SW, Kraemer, HC (2005). Predictors of treatment acceptance and completion in anorexia nervosa: implications for future study designs. Archives of General Psychiatry 62, 776781.
Kay, SR, Fiszbein, A, Opler, LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261276.
Mazure, CM, Halmi, KA, Sunday, SR, Romano, SJ, Einhorn, AM (1994). The Yale-Brown-Cornell Eating Disorder Scale: development, use, reliability and validity. Journal of Psychiatric Research 28, 425445.
McKnight, RF, Park, RJ (2010). Atypical antipsychotics and anorexia nervosa: a review. European Eating Disorders Review 18, 1021.
Papadopoulos, FC, Ekbom, A, Brandt, L, Ekselius, L (2009). Excess mortality, causes of death and prognostic factors in anorexia nervosa. British Journal of Psychiatry 194, 1017.
Singer, JD, Willett, JB (2003). Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. Oxford University Press: New York.
Sullivan, PF (1995). Mortality in anorexia nervosa. American Journal of Psychiatry 152, 10731074.

Keywords

Olanzapine versus placebo for out-patients with anorexia nervosa

  • E. Attia (a1) (a2) (a3), A. S. Kaplan (a4), B. T. Walsh (a1) (a2), M. Gershkovich (a5), Z. Yilmaz (a4), D. Musante (a6) and Y. Wang (a7)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed